ArticleBMC medical ethics2025
Three ethical approaches to expanding newborn screening through genomics: a critical comparative analysis.
Article in BMC medical ethics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Deciding "what" to screen for and "when": The importance of natural history information.American journal of human genetics · 2026Review
- Missing … presumed well? Legal and ethical aspects of 'missed cases' in genomic newborn screening.European journal of human genetics : EJHG · 2026Article
- Genomic newborn screening: data retention for research and clinical reuse.European journal of human genetics : EJHG · 2026Article
- Pediatric hearing loss in the universal newborn hearing screening era: etiologies, risk indicators, and clinical phenotypes.Frontiers in public health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe expansion of newborn bloodspot screening (NBS) programs through genomic sequencing is proposed as a way to revolutionise infant and lifelong healthcare. But for all its promise, profound ethical challenges arise too. Robust analysis of these ethical challenges, which include technological and commercial imperatives, as well as balancing individual rights with communal goods, first necessitates clarity as to which ethical approach is best suited to considering the use of genomics in NBS.
methodsWe use normative ethical analysis to provide a critical comparison of three ethical approaches to the expansion of NBS that shape debates over the implementation of genomic newborn screening (gNBS): liberal individualism, public health ethics, and genomic healthcare as a human right.
resultsWhile these approaches often overlap in practice, their distinct priorities illuminate tensions between individual autonomy, collective welfare, and rights-based claims to genomic information and attendant healthcare. We argue that public health ethics should be the primary ethical approach for gNBS. Yet, none of the three approaches are individually sufficient to fully address the ethical complexities involved. This is because each approach sheds useful light on distinct benefits and limitations of gNBS.
conclusionsWhile rigorous evidence-gathering to inform the ethical and societal impacts of gNBS is critical, this must be accompanied by - and interpreted through - normative ethical analysis that clearly articulates the values and tensions at stake. Overall, ethical implementation of gNBS requires a policy approach that (i) adopts public health ethics for programme design, (ii) operationalises select human-rights claims in accordance with established screening principles, and (iii) embeds liberal protections against state or parental overreach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.